Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer

NCT02353832 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT02353832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02353832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Phase 2
Overall status
Completed
Start date
November 6, 2014
Completion date
January 5, 2021
Enrollment
44 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer